Another phase 2 randomized controlled study conducted by Parker et al. in 2018 has also investigated efficacy and safety of human anti-IL-13 monoclonal antibody, tralokinumab, in patients with mild to moderate IPF [35], which indicated an acceptable safety and tolerability profile of IL-13 monoclonal antibody but didn’t achieve key efficacy endpoints. Here, IL13 is linked to idiopathic pulmonary fibrosis.